Progression free survival trang 1 tải miễn phí từ TAILIEUCHUNG

"Progression free survival" trang 1 - tải miễn phí từ Tailieuchung

Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice

Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice

10 9 1

A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy

A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy

11 75 1

High expression of the p53 isoform γ is associated with reduced progression-free survival in uterine serous carcinoma

High expression of the p53 isoform γ is associated with reduced progression-free survival in uterine serous carcinoma

10 58 1

Real life patterns of care and progression free survival in metastatic renal cell carcinoma patients: Retrospective analysis of cross-sectional data

Real life patterns of care and progression free survival in metastatic renal cell carcinoma patients: Retrospective analysis of cross-sectional data

7 30 1

Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy

Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy

5 30 1

Establishing the quantitative relationship between Lanreotide autogel®, chromogranin A, and progression-free survival in patients with nonfunctioning gastroenteropancreatic neuroendocrine tumors

Establishing the quantitative relationship between Lanreotide autogel®, chromogranin A, and progression-free survival in patients with nonfunctioning gastroenteropancreatic neuroendocrine tumors

10 40 0

Prior oral contraceptive use in ovarian cancer patients: Assessing associations with overall and progression-free survival

Prior oral contraceptive use in ovarian cancer patients: Assessing associations with overall and progression-free survival

7 61 1

Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer

Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer

8 44 1

Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu– positive advanced breast cancer: Results of the CECOG LaVie trial

Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu– positive advanced breast cancer: Results of the CECOG LaVie trial

7 57 1

Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib – results from a non-interventional multi-center study

Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib – results from a non-interventional multi-center study

8 57 0

MRI-based random survival Forest model improves prediction of progression-free survival to induction chemotherapy plus concurrent Chemoradiotherapy in Locoregionally Advanced nasopharyngeal carcinoma

MRI-based random survival Forest model improves prediction of progression-free survival to induction chemotherapy plus concurrent Chemoradiotherapy in Locoregionally Advanced nasopharyngeal carcinoma

12 7 1

Prognostic value of lymphocyte-monocyte ratio at diagnosis in Hodgkin lymphoma: A meta-analysis

Prognostic value of lymphocyte-monocyte ratio at diagnosis in Hodgkin lymphoma: A meta-analysis

12 73 0

Relationship between WBRT total dose, intracranial tumor control, and overall survival in NSCLC patients with brain metastases - a single-center retrospective analysis

Relationship between WBRT total dose, intracranial tumor control, and overall survival in NSCLC patients with brain metastases - a single-center retrospective analysis

12 83 1

Estrogen receptor β is associated with expression of cancer associated genes and survival in ovarian cancer

Estrogen receptor β is associated with expression of cancer associated genes and survival in ovarian cancer

9 44 0

Nomograms predict long-term survival for patients with periampullary adenocarcinoma after pancreatoduodenectomy

Nomograms predict long-term survival for patients with periampullary adenocarcinoma after pancreatoduodenectomy

11 36 1

Impact of diabetes mellitus on epithelial ovarian cancer survival

Impact of diabetes mellitus on epithelial ovarian cancer survival

6 26 1

Higher number of multidisciplinary tumor board meetings per case leads to improved clinical outcome

Higher number of multidisciplinary tumor board meetings per case leads to improved clinical outcome

9 83 0

Cisplatin-based chemotherapy with or without bevacizumab for Chinese postmenopausal women with advanced cervical cancer: A retrospective observational study

Cisplatin-based chemotherapy with or without bevacizumab for Chinese postmenopausal women with advanced cervical cancer: A retrospective observational study

8 56 0

Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: A retrospective analysis

Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: A retrospective analysis

13 67 0

A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen

A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen

8 31 1

Đã phát hiện trình chặn quảng cáo AdBlock

Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.